Prevalence, Risk Factors, and Type of Organism in Diabetic Patients with Onychomycosis
Keywords:
onychomycosis, diabetic, prevalence, risk factorAbstract
People living with diabetes could be at risk for fungal skin and nail infection. Improper diagnosis and treatment can result in several consequences, including disability.
Objective: This research aims to study prevalence, risk factors and type of organism in diabetic patients with onychomycosis.
Methods: This cross-sectional study was conducted at Burapha university hospital between March 1, 2020 and August 31, 2020. Inclusion criteria were diabetic patients age > 18 years and consent to participate in this study. Participants were interviewed on medical history, examined nails and toe nails. Laboratory investigation which included by potassium hydroxide (KOH) preparation, periodic acid schiff (PAS) stain and fungal culture were done if onychomycosis was suspected.
Results: Of 304 diabetic patients, the mean age was 63 years and 45.72% were male . There were 52 patients (17.11%) with onychomycosis. The most common organism was non-dermatophyte i.e. Aspergillus niger complex (10 patients). The least common organism was dermatophyte i.e. Trichosporon inkin (1 patients). Patients with onychomycosis were significantly older than non-onychomycosis group (70 vs 61 years). In univariate model, age > 60 years was significantly associated with onychomycosis (risk ratio 3.159, 95%CI = 1.599-6.240)(p = 0.0001)
Conclusions: Diabetic patients more than 60 years of age were at risk for onychomycosis. The most common cause of organism was Aspergillus spp. which is uncommon in other population. Fungal culture should be recommended among diabetic patients with onychomycosis.
Keywords: onychomycosis, diabetic, prevalence, risk factor
References
Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol 2019;80(4):835–51.
จรัสศีร ฬียาพรรณ. โรคเชื้อราที่เล็บ [อินเทอร์เน็ต]. 2560 [เข้าถึงเมื่อ 2 ตุลาคม 2563]. เข้าถึงได้จาก: https://www.si.mahidol.ac.th/th/healthdetail.asp?aid=1302
Morales-Cardona CA, Valbuena-Mesa MC, Alvarado Z, Solorzano-Amador A. Non-dermatophyte mould onychomycosis: a clinical and epidemiological study at a dermatology referral centre in Bogota, Colombia. Mycoses 2014;57(5):284–93.
Abdullah L, Abbas O. Common nail changes and disorders in older people: diagnosis and management. Can Fam Physician Med Fam Can 2011;57(2):173–81.
Elewski BE, Tosti A. Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy. J Clin Aesthetic Dermatol 2015;8(11):38–42.
Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol JEADV 2004;18(1):48–51.
Assadamongkol R, Lertwattanarak R, Wannachalee T, Bunyaratavej S, Leeyaphan C, Matthapan L. Prevalence, risk factors, and type of organism in fungal foot infection and toenail onychomycosis in Thai diabetic patients. J Med Assoc Thail Chotmaihet Thangphaet 2016;99(6):659–64.
Warshaw EM, Foster JK, Cham PMH, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis: NailQoL. Int J Dermatol 2007;46(12):1279–86.
Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol EJD 2000;10(5):379–84.
Moreno G, Arenas R. Other fungi causing onychomycosis. Clin Dermatol 2010;28(2):160–3.
Papini M, Cicoletti M, Fabrizi V, Landucci P. Skin and nail mycoses in patients with diabetic foot. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr 2013;148(6):603–8.
Wijesuriya TM, Weerasekera MM, Kottahachchi J, Ranasinghe KNP, Dissanayake MSS, Prathapan S, et al. Proportion of lower limb fungal foot infections in patients with type 2 diabetes at a tertiary care hospital in Sri Lanka. Indian J Endocrinol Metab 2014;18(1):63–9.
Farwa U, Abbasi SA, Mirza IA, Amjad A, Ikram A, Ikram A, et al. Non-dermatophyte moulds as pathogens of onychomycosis. J Coll Physicians Surg--Pak JCPSP 2011;21(10):597–600.
Martínez-Herrera EO, Arroyo-Camarena S, Tejada-García DL, Porras-López CF, Arenas R. Onychomycosis due to opportunistic molds. An Bras Dermatol 2015;90(3):334–7.
Motamedi M, Ghasemi Z, Shidfar MR, Hosseinpour L, Khodadadi H, Zomorodian K, et al. Growing incidence of non-dermatophyte onychomycosis in Tehran, Iran. Jundishapur J Microbiol 2016;9(8):e40543.
Wijesuriya T, Kottahachchi J, Gunasekara TDCP, Bulugahapitiya U, Ranasinghe KNP, Neluka Fernando S, et al. Aspergillus species: an emerging pathogen in onychomycosis among diabetics. Indian J Endocrinol Metab 2015;19(6):811.
Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol 2012;66(3):494–502.
Bowyer P, Moore CB, Rautemaa R, Denning DW, Richardson MD. Azole antifungal resistance today: focus on Aspergillus. Curr Infect Dis Rep 2011;13(6):485–91.
Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol 2014;171(5):937–58.
Downloads
Published
Versions
- 2026-02-11 (2)
- 2021-04-30 (1)
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี